Investigational drug · Phase 2
HA131
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma (HCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HA131"
First trial start
2025
Dec 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HA131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HA131" as an intervention, largest first.
- Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerPivotal-lookingNot yet recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07282509 · 116 participants (planned) · Start Dec 23, 2025 · Primary completion Jun 26, 2028
Drug: HA131; Enlonstobart Injection and 2 more · For: Advanced Hepatocellular Carcinoma (HCC)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Hepatocellular Carcinoma (HCC)
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- AK105Phase 31 trial
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC)
- B7-H3 CAR-NKEB-G3B7-NK dual-target CAR-NK cells, Dual-target GPC3Phase 22 trials
Beijing Biotech · Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Relapsed Neuroblastoma
- WGI-0301Phase 22 trials
Zhejiang Haichang Biotech Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.